Best of Hematology and Breast Cancer 2026 - Augusta

Best of Hematology and Breast Cancer 2026 is organized by Binaytara Foundation (BTF) and will be held on Jan 31, 2026 at Crowne Plaza North Augusta by IHG, North Augusta, South Carolina, United States of America.

Description:
The Best of Hematology and Breast Cancer 2026 Conference in Augusta is a CE-accredited, in-person educational activity designed to provide oncology and hematology professionals with timely updates in both hematologic disorders and breast cancer care. 

This dynamic program will feature expert-led case-based discussions, didactic presentations, and tumor board-style sessions that address both common and complex challenges in hematology and breast cancer management. Attendees will gain insights into recent advances in benign hematology, hematologic malignancies, and breast cancer subtypes, including hormone receptor-positive, HER2-positive, triple-negative, and HER2-low disease.

In addition to scientific sessions, the agenda includes dedicated time for networking and interactive panel discussions, creating opportunities for participants to engage directly with faculty and peers. The conference will also spotlight Binaytara’s initiatives to reduce disparities in cancer care, emphasizing the importance of access and equity alongside cutting-edge science.

Key Highlights:

• Comprehensive Hematology Updates: From bleeding disorders, ITP/TTP, and bone marrow failure to AML, ALL, MPN, CML, lymphomas, CLL, and multiple myeloma.
• Breast Cancer Best Practices: Latest evidence in surgery, radiotherapy, hormone receptor-positive, HER2-positive, and triple-negative/HER2-low breast cancer.
• Interactive Learning: Case-based discussions, tumor board sessions, and panel debates to bridge research with real-world decision-making.
• CE-Credit: Accredited education that supports ongoing professional development and board certification requirements.

Learning Objectives:

• Summarize the latest updates from ASH25 and SABCS25, focusing on their implications for clinical practice in managing hematologic disorders and breast cancer.
• Assess new therapeutic options for benign and malignant hematologic disorders and breast cancer, including appropriate indications and contraindications presented at ASH25 and SABCS25.
• Examine the study design, primary endpoints, and impact of recent and ongoing clinical trials from ASH25 and SABCS25 that have influenced current standards of care.
• Incorporate evolving diagnostic, prognostic, and therapeutic strategies from ASH25 and SABCS25 into patient management for hematologic disorders and breast cancer.
• Apply emerging data from clinical trials and updated expert guidelines from ASH25 and SABCS25 to individualize patient management strategies.